Amendment Dated: March 30, 2007

Supplemental Reply to Office Action of December 5, 2006

IN THE CLAIMS

1. (Currently Amended) An immunoassay for assaying a soluble target antigen or

antibody present in a whole blood sample, comprising the steps of:

(a) mixing the whole blood sample with insoluble carrier particles which are sensitized

with an antigen against the soluble target antibody or an antibody against the soluble target

antigen, wherein said particles are smaller than erythrocytes, to cause an immune agglutination

reaction resulting in an immune agglutination reaction mixture comprising agglutinated insoluble

carrier particles and unagglutinated insoluble carrier particles;

(b) introducing the immune agglutination reaction mixture to a flow cell, irradiating the

particles passing through the flow cell with laser light, and detecting scattered light generated

thereby;

(c) setting a first threshold value for distinguishing unagglutinated insoluble carrier

particles from agglutinated insoluble carrier particles and a second threshold value for

distinguishing the agglutinated insoluble carrier particles from blood cells with regard to

intensity of the scattered light;

(d) distinguishing and counting the unagglutinated insoluble carrier particles, the

agglutinated insoluble carrier particles and the blood cells from the intensity of the scattered light

detected in the step (b), in reference to the first and second threshold values set in the step (c);

(e) calculating a degree of agglutination from the number of the unagglutinated insoluble

carrier particles and the number of the agglutinated insoluble carrier particles;

2

MSW/TJS/ma

Docket No.: 0397-0438P

Amendment Dated: March 30, 2007

Supplemental Reply to Office Action of December 5, 2006

(f) converting the degree of agglutination into a concentration of the soluble target

antigen or antibody in the whole blood sample using a calibration curve showing a relationship

between a degree of agglutination and a concentration of a soluble target antigen or antibody;

and

(g) obtaining a corrected concentration of the soluble target antigen or antibody based on

the following formula:

$$C = CO / (1-B-A) (1-B/A),$$

wherein C is a corrected concentration, CO is the concentration of the soluble target antigen or antibody present in the whole blood sample, B is the number of blood cells and A is a constant.

2-4. (Cancelled)

5. (Currently Amended) An immunoassay for assaying a soluble target antigen or

antibody present <u>in</u> a whole blood sample, comprising the steps of:

(a) mixing the whole blood sample with insoluble carrier particles which are sensitized with

an antigen against the soluble target antibody or an antibody against the soluble target antigen,

wherein said particles are smaller than erythrocytes, to cause an immune agglutination reaction

resulting in an immune agglutination reaction mixture comprising agglutinated insoluble carrier

particles and unagglutinated insoluble carrier particles;

Docket No.: 0397-0438P

Docket No.: 0397-0438P

(b) introducing the immune agglutination reaction mixture to a flow cell, irradiating the

particles passing through the flow cell with laser light, and detecting scattered light generated

thereby;

(c) setting a first threshold value for distinguishing unagglutinated insoluble carrier

particles from agglutinated insoluble carrier particles and a second threshold value for

distinguishing the agglutinated insoluble carrier particles from blood cells with regard to

intensity of the scattered light;

(d) distinguishing and counting the unagglutinated insoluble carrier particles, the

agglutinated insoluble carrier particles and the blood cells from the intensity of the scattered light

detected in the step (b), in reference to the first and second threshold values set in the step (c);

(e) calculating a degree of agglutination from the number of the unagglutinated insoluble

carrier particles and the number of the agglutinated insoluble carrier particles;

(f) converting the degree of agglutination into a concentration of the soluble target

antigen or antibody in the whole blood sample using a calibration curve showing a relationship

between a degree of agglutination and a concentration of soluble target antigen or antibody; and

(g) obtaining a mean corpuscular volume (MCV) in the whole blood sample, wherein the

concentration of the soluble target antigen or antibody present in the whole blood sample is

corrected according to the MCV measurement and the number of blood cells.

6. (Previously Presented) The immunoassay according to claim 5, wherein the mean

corpusculer volume (MCV) is obtained from the scattered lights detected in the step (b), in

reference to the threshold values set in the step (c).

Docket No.: 0397-0438P

7. (Previously Presented) The immunoassay according to claim 5, wherein correction according to the MCV measurement and the number of blood cells is made by use of the following formula:

$$C = CO / \{1 - (B/A) X (MCV / D)\},\$$

wherein C, CO, A and B are the same as defined above, MCV is the MCV measurement of the sample and D is a constant.

- 8. (Previously Presented) The immunoassay according to Claim 1, wherein the scattered light is forward scattered light.
- 9. (Previously Presented) The immunoassay according to Claim 1, wherein the size of the insoluble carrier particles is 0.1 μ m to 1.0 μ m.
- 10. (Previously Presented) The immunoassay according to Claim 1, wherein, in the step (a), the temperature is from 20 to 50°C and the time is from 15 seconds to 20 minutes.
 - 11-12. (Cancelled).
- 13. (Currently Amended) An immunoassay apparatus for assaying a soluble target antigen or antibody present in a whole blood sample, comprising:

a reaction part for mixing the whole blood sample with insoluble carrier particles which

are sensitized with an antigen against the soluble target antibody or an antibody against the

soluble target antigen, wherein said particles are smaller than erythrocytes, to cause an immune

agglutination reaction resulting in an immune agglutination reaction mixture comprising

agglutinated insoluble carrier particles and unagglutinated insoluble carrier particles;

a dispenser for introducing the resulting immune agglutination reaction mixture to a flow

cell,

a laser for irradiating the particles passing through the flow cell with laser light,

a photo acceptance unit for detecting scattered light generated thereby,

a signal processor for converting the scattered light to an electrical signal, and

a data processor configured for setting a first threshold value for distinguishing

unagglutinated insoluble carrier particles from agglutinated insoluble carrier particles and a

second threshold value for distinguishing the agglutinated insoluble carrier particles from blood

cells with regard to the signal based on intensity of the scattered light; for distinguishing and

counting the unagglutinated insoluble carrier particles, the agglutinated insoluble carrier particles

and the blood cells according to the set first and second threshold values; for calculating a degree

of agglutination from the number of the unagglutinated insoluble carrier particles and the number

of the agglutinated insoluble carrier particles; for converting the degree of agglutination into a

concentration of the soluble target antigen or antibody in the whole blood sample using a

calibration curve showing a relationship between a degree of agglutination and a concentration

of a soluble target antigen or antibody; and for obtaining a corrected concentration of the soluble

target antigen or based on the following formula:

6

MSW/TJS/ma

Amendment Dated: March 30, 2007

Supplemental Reply to Office Action of December 5, 2006

C = CO / (1 - B - A) (1 - B/A),

wherein C is a corrected concentration, CO is the concentration of the soluble target antigen or

antibody present in the whole blood sample, B is the number of blood cells and A is a constant.

14. (Cancelled)

15. (Previously Presented) The immunoassay according to Claim 5, wherein the

scattered light is forward scattered light.

Birch, Stewart, Kolasch & Birch, LLP

16. (Previously Presented) The immunoassay according to Claim 5, wherein the size of

the insoluble carrier particles is 0.1 μ m to 1.0 μ m.

17. (Previously Presented) The immunoassay according to Claim 5, wherein, in the step

(a), the temperature is from 20 to 50 °C and the time is from 15 seconds to 20 minutes.

18. (Previously Presented) An immunoassay apparatus for assaying a soluble target

antigen or antibody present in a whole blood sample, comprising:

a reaction part for mixing the whole blood sample with insoluble carrier particles which

are sensitized with an antigen against the soluble target antibody or an antibody against the

soluble target antigen, wherein said particles are smaller than erythrocytes, to cause an immune

agglutination reaction resulting in an immune agglutination reaction mixture comprising

agglutinated insoluble carrier particles and unagglutinated insoluble carrier particles;

7

MSW/TJS/ma

Docket No.: 0397-0438P

Docket No.: 0397-0438P

a dispenser for introducing the resulting immune agglutination reaction mixture to a flow

cell,

a laser for irradiating the particles passing through the flow cell with laser light,

a photo acceptance unit for detecting scattered light generated thereby,

a signal processor for converting the scattered light to an electrical signal, and

a data processor, wherein said data processor is:

configured for setting a first threshold value for distinguishing unagglutinated

insoluble carrier particles from agglutinated insoluble carrier particles and a second

threshold value for distinguishing the agglutinated insoluble carrier particles from blood

cells with regard to the signal based on intensity of the scattered light;

configured for distinguishing and counting the unagglutinated insoluble carrier

particles, the agglutinated insoluble carrier particles and the blood cells according to the

set first and second threshold values;

configured for calculating a degree of agglutination from the number of the

unagglutinated insoluble carrier particles and the number of the agglutinated insoluble

carrier particles;

configured for converting the degree of agglutination into a concentration of the

soluble target antigen or antibody in the whole blood sample using a calibration curve

showing a relationship between the degree of agglutination and a concentration of a

soluble target antigen or antibody; and

configured for obtaining a mean corpusculer volume (MCV) in the whole blood

sample,

8

MSW/TJS/ma

Amendment Dated: March 30, 2007

Supplemental Reply to Office Action of December 5, 2006

Docket No.: 0397-0438P

wherein the concentration of the soluble target antigen or antibody present in the whole

blood sample is corrected according to the MCV measurement and the number of blood cells.

19. (Previously Presented) The immunoassay apparatus according to Claim 13, wherein

the size of the insoluble carrier particles is 0.1 μ m to 1.0 μ m.

20. (Previously Presented) The immunoassay apparatus according to Claim 18, wherein

the size of the insoluble carrier particles is 0.1 μ m to 1.0 μ m.